Multi-Centre Based Evaluation of the Performance and Safety of the Corsano CardioWatch 287-2 Blood Pressure Monitoring Device at Wrist Against BP-Cuff Measurements (COR-BP) (COR-BP)
The Corsano CardioWatch 287-2 is a medical wearable device that can monitor blood pressure. The device has been validated using clinical trials in hospitals. The aim of this study is to further evaluate blood pressure measurements by the CardioWatch 287-2 in the intended remote setting across various demographic groups.
Primary objective: To assess the difference in blood pressure measurements obtained by the Corsano CardioWatch 287-2 and auscultatory blood pressure monitoring over a period of 31 days.
Secondary objective: To assess the usability of the Corsano CardioWatch 287-2 from a patient perspective.
Participants receiving multiple standardized paired auscultatory and Corsano CardioWatch blood pressure measurements over a 31-day period. The study group will include patients of different ages (above the age of 22 years), genders, and demographics.
調査の概要
状態
条件
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Nova Jaspers, MSc
- 電話番号:+31616407778
- メール:nova.jaspers@corsano.com
研究連絡先のバックアップ
- 名前:Elena Ferraris, MSc
- メール:elena@corsano.com
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Participants must be able to provide informed consent to participate.
- Participants must be willing and able to comply with all of the study procedures and return for at least 3 visits.
- Participant or witness must be able to read or write in Dutch or English.
- Applicable for group A: Participant must be 22 to 50 years of age.
- Applicable for group B: Participant must be over 50 years of age.
Exclusion Criteria:
- Participants with compromised circulation, injury, or physical malformation of the equipment test sites or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized).
- Female participants who are known to be pregnant or who are trying to get pregnant confirmed by a day 1 positive urine pregnancy test unless the study participant is known to be not of child-bearing potential.
- Participants with known clotting disorders or currently taking a prescription blood thinner.
- Other known health conditions that will prevent safe participation in the study upon disclosure in Health Assessment Short Form or verbally.
- Participants suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including tachycardia (heart rate at rest > 120bpm) and atrial fibrillation.
- Participants suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR < 60mL / min / 1.73 m2), hyper- / hypothyroidism, pheochromocytoma or arteriovenous fistula.
- Participants with known aortic arch pathology or prior surgical intervention involving the aortic arch or descending aorta (e.g., coarctation repair, vascular grafting, or stenting), which may interfere either with accurate peripheral blood pressure measurement.
- A wrist circumference below 14 cm or above 23 cm.
- An upper arm circumference < 22cm or > 42cm.
- Any subject that, in the opinion of the investigator, does not exhibit any phenotype relevant to the objectives of this study (i.e. to ensure all sub-groups have adequate representation).
- Any condition or circumstance that, in the opinion of the investigator, may preclude study completion, interfere with accurate data collection, bias the results, by instance a subject presenting a lateral Blood Pressure difference at screening of more than 15 mmHg for the systolic and/or more than 10 mmHg for the diastolic.
Additional criteria that will be pursued for ensuring demographic diversity consist of the following patient characteristics according to FDA recommendations concerning the diversity of clinical trial populations [6]:
Gender, at least:
- 40% female;
- 40% male.
Skin Colour, at least:
- 25% Monk skin tone (MST) 1-3;
- 25% MST 4-6;
- 25% MST 7-10 including subjects with MST 9 and MST 10.
BMI, at least:
- 5% Underweight (<18.5)
- 20% Normal weight (18.5-24.9)
- 20% Overweight (25-29.9)
- 20% Obese (≥30.0)
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Group A
Group A consists of patients 22 to 50 years of age.
Group A involves patients from multiple demographic groups.
|
Non-invasive blood pressure measurements with the Corsano CardioWatch 287-2 wearable over a period of 31 days.
他の名前:
Auscultatory blood pressure measurements in supine and sitting position.
|
|
Group B
Group B consists of patients aged 50 years and above.
Group B involves patients from multiple demographic groups.
|
Non-invasive blood pressure measurements with the Corsano CardioWatch 287-2 wearable over a period of 31 days.
他の名前:
Auscultatory blood pressure measurements in supine and sitting position.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Validate blood pressure measurements Corsano CardioWatch 287-2
時間枠:31 days
|
The main objective of this study is to assess the difference in blood pressure measurements obtained by the Corsano CardioWatch 287-2 and the gold standard auscultatory measurements over a 31-day calibration interval, including evaluation of measurement stability and response to induced blood pressure changes.
monitoring over a period of 31 days; to evaluate the performance of the Corsano CardioWatch 287-2.
|
31 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assess usability
時間枠:31 days
|
The secondary objective of this study is to assess the usability of the Corsano CardioWatch 287-2 from a patient perspective in a remote care setting.
This will be done by using a questionnaire that assesses the usability, comfort, and noticeability of wearing the CardioWatch 287-2.
|
31 days
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- COR-BP
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。